BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Holdings Lessened by Citigroup Inc.

Citigroup Inc. reduced its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating) by 28.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 341,218 shares of the biotechnology company’s stock after selling 133,361 shares during the period. Citigroup Inc.’s holdings in BioCryst Pharmaceuticals were worth $3,917,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in BioCryst Pharmaceuticals by 40.3% in the first quarter. Vanguard Group Inc. now owns 13,207,040 shares of the biotechnology company’s stock worth $214,746,000 after purchasing an additional 3,794,135 shares in the last quarter. State Street Corp boosted its holdings in BioCryst Pharmaceuticals by 47.5% in the second quarter. State Street Corp now owns 11,004,803 shares of the biotechnology company’s stock worth $116,431,000 after purchasing an additional 3,542,051 shares in the last quarter. Loomis Sayles & Co. L P boosted its holdings in BioCryst Pharmaceuticals by 64.0% in the first quarter. Loomis Sayles & Co. L P now owns 2,356,216 shares of the biotechnology company’s stock worth $38,312,000 after purchasing an additional 919,104 shares in the last quarter. Millennium Management LLC boosted its holdings in BioCryst Pharmaceuticals by 3,445.8% in the second quarter. Millennium Management LLC now owns 1,948,595 shares of the biotechnology company’s stock worth $20,616,000 after purchasing an additional 1,893,640 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in BioCryst Pharmaceuticals by 0.9% in the second quarter. Northern Trust Corp now owns 1,816,884 shares of the biotechnology company’s stock worth $19,223,000 after purchasing an additional 16,986 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Trading Up 0.8 %

Shares of BioCryst Pharmaceuticals stock opened at $8.44 on Monday. BioCryst Pharmaceuticals, Inc. has a 1-year low of $7.20 and a 1-year high of $15.43. The firm’s 50-day moving average price is $8.19 and its two-hundred day moving average price is $9.94. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -6.98 and a beta of 2.01.

BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) last announced its quarterly earnings data on Wednesday, May 3rd. The biotechnology company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.02. The business had revenue of $68.80 million during the quarter, compared to analyst estimates of $71.44 million. During the same quarter in the prior year, the company earned ($0.40) earnings per share. The company’s quarterly revenue was up 37.9% on a year-over-year basis. As a group, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -1.03 EPS for the current year.

Wall Street Analysts Forecast Growth

BCRX has been the subject of a number of research analyst reports. Needham & Company LLC reissued a “buy” rating and set a $14.00 target price on shares of BioCryst Pharmaceuticals in a research report on Thursday, April 20th. JMP Securities reissued a “market outperform” rating and issued a $16.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday, February 22nd. Evercore ISI dropped their price target on shares of BioCryst Pharmaceuticals from $13.00 to $10.00 and set an “outperform” rating for the company in a research report on Thursday, April 20th. StockNews.com lowered shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, May 12th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday, February 22nd. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

BioCryst Pharmaceuticals Profile

(Get Rating)

BioCryst Pharmaceuticals, Inc is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The firm focuses on the treatment of rare diseases in which unmet medical needs exist and an enzyme in the biological pathway of the disease. Its programs include BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for marburg virus disease and yellow fever.